Neoadjuvant Daromun + Surgery (Melanoma) - Clinical Trial
¿Cuál es el Propósito de este estudio?
We are doing this study to find out if an investigational called Daromun (the study drug) is a safe and effective treatment for melanoma. We want to know if treating people with the drug before surgery to remove tumors can lower the chance of cancer recurrence.
Stage IIIB and IIIC Metastatic Melanoma
¿Quién puede participar en el Estudio?
Adults ages 18+ who:
- Are diagnosed with stage IIIB or IIIC metastatic melanoma
- Are eligible to have surgical removal of all metastases
- Have injectable cutaneous, subcutaneous, or nodal lesions
For more information about who can join this study, please contact the study team at ivy.belskie@duke.edu.
¿Qué Implica?
If you choose to join this study, you will go through a 2-week long screening process to see if you are eligible.
During screening, you will:
- Hacer un examen físico
- Responder encuestas
- Realizar extracciones de sangre
- Proporcionar muestras de orina
- Have different images of your tumor(s) taken (ultrasound, CT, PET/CT, MRI)
If you are found to be eligible, you will proceed to the study drug period. During this period, you will get a random assignment (50/50 chance) to 1 of 2 arms in the study:
- Arm 1: the study drug plus surgery and adjuvant therapy (the study doctor's choice from a pre-approved list)
- Arm 2: surgery and adjuvant therapy (the study doctor's choice from a pre-approved list)
The study drug consists of two recombinantly produced, fully human fusion proteins named L19IL2 and L19TNF. It will be administered directly into your tumors each week for 4 weeks before your surgery if you are assigned to Arm 1 of the study.
Detalles del Estudio
